Curated Video
Sunita Williams' Latest Picture Show Excessive Weight loss, Astronaut's Health Concerns NASA
NASA has highlighted new health concerns for astronaut Sunita Williams as she continues her unexpectedly long mission aboard the International Space Station (ISS). Originally scheduled for an eight-day trip, Williams' stay was extended...
Curated Video
Astronaut's Health Concerns NASA: Williams Seen Undergone Excessive Weight Loss In Latest Pictures
NASA has highlighted new health concerns for astronaut Sunita Williams as she continues her unexpectedly long mission aboard the International Space Station (ISS). Originally scheduled for an eight-day trip, Williams' stay was extended...
Curated Video
Are weight-loss drugs bloated with risk?
A University of Alberta study shows that people on popular weight-loss drugs shedded pounds — but up to 40 per cent of weight lost was muscle. Professor Carla Prado explains the risks and unintended side effects of these new drugs.
Curated Video
Nimbu paani and more: 5 weight loss drinks that actually work
This video transcription discusses the benefits of morning drinks in aiding belly fat loss, especially for individuals following a weight loss program. It highlights the effectiveness of various drinks such as jeera water, chaas...
Curated Video
5 everyday healthy hacks for an impressive weight loss
In this video transcription, various everyday hacks for effective weight loss are revealed, highlighting the importance of a highprotein breakfast for weight loss success. The transcription also discusses the benefits of premeal water...
Curated Video
Eli Lilly’s Orforglipron shows potential for weight loss and diabetes control
Eli Lilly's Phase 3 study highlights the effectiveness of Orforglipron in lowering blood sugar and promoting weight loss, potentially offering a convenient alternative to GLP-1 injections. (Scripps News)
Bloomberg
Novo's Next-Gen Obesity Drug Disappoints in a Trial
Novo Nordisk shares plunged the most since December after another disappointment for the drugmaker's next-generation shot CagriSema. The medicine helped patients with diabetes lose 15.7% of their weight over 68 weeks, compared with 3.1%...
Bloomberg
Novartis CEO Says They Will Have to 'Tackle Rhetoric' in US Healthcare
Vas Narasimhan, Novartis CEO speaks with Francine Laqcua about the Trump administration and the future of pharmaceuticals on the sidelines of the 2025 World Economic Forum in Davos.
(Republishes to correct the spelling of Novartis in...
Bloomberg
Structure CEO on Obesity Drugs: Oral Pills Are the Solution
Structure Therapeutics CEO Raymond Stevens discusses obesity drugs and the company's expansion plans with Katie Greifeld at the JPMorgan Health-Care Conference in San Francisco.
Bloomberg
Regeneron CSO Yancopoulos on Weight-Loss Drugs, Pipeline
Regeneron co-Chair, President and CSO George Yancopoulos discusses the company's planned weight-loss drugs with Katie Greifeld at the JPMorgan Healthcare Conference in San Francisco.
Bloomberg
Takeda CEO Weber on Drug Pipeline, Geopolitical Risks
Takeda Pharmaceutical CEO Christophe Weber discusses the company's drug pipeline and current geopolitical risks with Katie Greifeld at the JPMorgan Health Care Conference in San Francisco.
Bloomberg
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing
Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks...
Bloomberg
David Rubenstein Remembers Jimmy Carter
Carlyle Group co-founder and co-chairman and host of "Peer-to-Peer Conversations" David Rubenstein talks about the rising popularity of weight loss drugs and his interview with Eli Lilly CEO Dave Ricks. He also talks about the legacy of...
Bloomberg
Novo Selloff Is an Overreaction, Barclays' Field Says
Emily Field, Barclays' head of European pharmaceutical research, reacts to the selloff in Novo Nordisk's shares after its experimental obesity shot CagriSema failed to meet expectations. She speaks on "Bloomberg Open Interest."
Bloomberg
Rubenstein on Lilly, New FTC Head, Library of Congress
The Carlyle Group co-founder and Bloomberg Host David Rubenstein previews his next episode of "Peer-to-Peer" Conversations. He'll talk to the Librarian of Congress. He also sat down with the CEO of Eli Lilly and spoke about their...
Bloomberg
Lilly Will Test Obesity Drugs on Addiction, CEO Says
Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines can also be used to treat addictive behaviors like alcohol abuse, smoking and drug addiction, Chief Executive Officer Dave Ricks said. These medicines can...
Bloomberg
Lilly's Zepbound Beats Wegovy in Weight-Loss Drug Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S's Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50...
Curated Video
Smoothie King adds GLP-1 weight loss support friendly products to its menu
Smoothie King has now added menu items the company says pair well with diet drugs. (Scripps News)
Curated Video
Eli Lilly releases discounted single-dose vials of Zepbound weight loss drug
Those who used 5-milligram doses had an average 15% weight loss after 72 weeks. (Scripps News)
Curated Video
America's Poison Centers: 69% rise in GLP-1 overdose calls in the first half of the year
Health officials are warning some patients have made themselves sick after messing up dosing a version of popular weight loss drugs. (Scripps News)
Curated Video
Drugmaker says weight loss drugs reduced Type 2 diabetes risk by 94%
Eli Lilly says one of its weight-loss drugs can greatly reduce the risk of developing diabetes among a group highly at risk for the disease. (Scripps News)
Curated Video
The politics behind insurance companies covering weight-loss drugs
Out-of-pocket costs for some prescription weight-loss drugs can hover around $1,000 per month for some individuals.
Bloomberg
Ozempic Could Impact Food Company Earnings
A new class of weight-loss drugs has rattled global equity markets, sending shares of everything from food and beverage companies to medical-device makers tumbling. As earnings season kicks into high gear, firms are expected to reveal if...
Bloomberg
Weighty Matters
Everything comes with its fair share of side effects. People are rapidly dropping weight on Ozempic, which means less consumption of foods such as sweets, treats and snacks. We take a look at the economic impact of appetite-suppressing...